A short article “Can we expect a pronounced effect of neprilysin inhibition by LCZ696 on the levels of immunoreactive BNP? ” written by Dr. Alexander Semenov, one of HyTest’s scientists, was published in NACB Scientific Shorts in October.

LCZ696 (Entresto™, Novartis) is a heart failure drug recently approved by FDA. Since the drug inhibits degradation of BNP, it has been speculated that this might cause false results in assays designed to detect BNP. At HyTest we have been studying ProBNP, NT-proBNP and BNP for several years and we have developed a panel of monoclonal antibodies for all different forms as well as three different recombinant proteins. Use of these reagents has enabled us to study the effect of Entresto on different types of BNP immunoassays.

NACB Scientific Shorts are brief articles written by scientific experts. NACB is the Academy of AACC.

Read the NACB Shorts on LCZ696 and immunoreactive BNP

Recent publications by HyTest scientists related to LCZ696 and BNP
Semenov AG and Katrukha AG (2016) Analytical issues with natriuretic peptides – has this been overly simplified? eJIFCC 27(3):189-207.
Semenov AG and Katrukha AG (2016) Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter. Clin Chem. 62(4):617-22.

All BNP related articles authored or co-authored by HyTest scientists.